Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Remission

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 1, 2000, Pages 50-57

  Linker, Charles A ^a,g   Ries, Curt A ^a   Damon, Lloyd E ^a   Sayre, Peter ^a   Navarro, Willis ^a   Rugo, Hope S ^a   Rubin, Arnold ^b   Case, Delvyn ^c   Crilley, Pamela ^d   Topolsky, David ^d   Brodsky, Isadore ^d   Zamkoff, Ken ^e   Wolf, Jeffrey L ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b St Joseph's Medical Center   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f Alta Bates Medical Center   (United States)

^g NONE   (United States)

Author keywords

Acute myeloid leukemia; Autologous transplantation; First remission treatment strategy

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CD34 ANTIGEN; CYTARABINE; ETOPOSIDE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BLOOD; CLINICAL TRIAL; CYTAPHERESIS; CYTOGENETICS; DISEASE FREE SURVIVAL; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTE COUNT; MIDDLE AGED; MULTICENTER STUDY; MYELOID LEUKEMIA; RECURRENT DISEASE; STEM CELL MOBILIZATION; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYTAPHERESIS; CYTARABINE; CYTOGENETICS; DISEASE-FREE SURVIVAL; ETOPOSIDE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LEUKOCYTE COUNT; MIDDLE AGED; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033629775     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70052-8     Document Type: Article

References (28)

1. Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycylcophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998;22:865-872.
2. Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993;81:311-318.
3. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood. 1990;75:1606-1614.
4. Stein AS, O'Donnell MR, Chai A, et al. In vivo purging with high-dose cytarabine followed by high-dose chemotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission J Clin Oncol. 1996;14:2206-2216.
5. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;39:1649-1656.
6. Mayer RJ, Davis RB, Schiffer CA, et al., for the Cancer and Leukemia Group B. Intensive post remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896-903.
7. Bloomfield C, Lawrence D, Arthur DC, et al. Curative impact of intensification with high-dose cytarabine in acute myeloid leukemia varies by cytogenetic group [abstract]. Blood. 1994;84:111a.
8. Frassoni F, Labopin M, Gluckman E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time: a report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1996;17:13-18.
9. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990; 76:1867-1871.
10. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998;91:1083-1090.
11. Zittoun RA, Mandelli F, Willemze R, et al., for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med. 1995;332:217-223.
12. Asou N, Adachi K, Tamura J, et al, for the Japan Adult Leukemia Study Group. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol. 1998;16:78-85.
13. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 1995;85:2643-2653.
14. Fenaux P, Chastang C, Castaigne S, et al. The European APL Group. Long term follow-up confirms the superiority of ATRA combined with chemotherapy (CT) over CT alone in newly diagnosed acute promyelocytic leukemia (APL 91 trial) [abstract]. Blood. 1997;90:331a.
15. Grimwade D, Walker H, Oliver F, et al., on behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
16. Garson OM, Matthews JP, Bishop JF, and the Australian Leukaemia Study Group. Prognostic significance of cytogenetic abnormalities in adult acute myeloid leukemia patients treated with high dose cytarabine [abstract]. Blood. 1995;86:600a.
17. Hiddemann W, Fonatsch C, Wörmann B, et al., for the German AML Cooperative Group. Cytogenetic subgroups of AML and outcome from the high dose versus conventional dose ara-c as part of double induction therapy [abstract]. Blood.1995;86:267a.
18. Gale RP, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant. 1995;6:203-208.
19. Keating S, Suciu S, de Witte T, et al, for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. Prognostic factors of patients with acute myeloid leukemia allografted in first complete remission: an analysis of the EORTC-GIMEMA AAML 8A trial. Bone Marrow Transplant. 1996;17:993-1001.
20. Nevill T, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92:1910-1917.
21. Ferrant A, Labopin M, Frassoni F, et al, on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EMBT). Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Blood. 1997;90:2931-2938.
22. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood. 1998;92:1073-1090.
23. Laporte J, Douay L, Lopez M, et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood. 1994;84:3810.
24. Stein AS, O'Donnell MR, Slovak M, et al. Do cytogenetics predict outcome of autologous bone marrow transplantation (ABMT) for acute myelogenous leukemia in 1st remission? [abstract] Blood. 1996;88:485a.
25. Ball ED, Phelps V, Wilson J. Acute bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow [abstract]. Blood. 1996;88:485a.
26. Schiller G, Miller T, Lee M, et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine/G-CSF-based consolidation for adults with acute myelogenous leukemia in first complete remission [abstract]. Blood. 1996;88:127a.
27. Mehta J, Powles R, Singhal S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant. 1995;16:499-506.
28. Stein A, O'Donnell MR, Parker P, et al. Interleukin 2 post high dose cytarabine mobilized autologous stem cell transplant for adult patients with acute myelogenous leukemia in first complete remission [abstract]. Blood. 1998;92:292a.